Eurofins Scientific has filed a patent for methods and kits to identify interactions between test compounds and phage-displayed protein domains like SH2. The method involves screening for binding of test compounds to the protein domain of interest using a reference ligand on a solid support. GlobalData’s report on Eurofins Scientific gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eurofins Scientific, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Eurofins Scientific's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Screening test compounds binding to phage-displayed protein domain
See Also:
The patent application (Publication Number: US20240018509A1) describes a method for screening test compounds that bind to a phage-displayed protein domain of interest. The method involves contacting a reference ligand immobilized on a solid support with the protein domain of interest in the presence and absence of the test compound. The binding of the protein domain to the reference ligand is then detected, with a decrease in binding indicating that the test compound binds to the protein domain. The protein domain of interest in this method is specifically identified as an SH2 domain, with the test compounds being small molecules or candidate pharmaceuticals.
Furthermore, the method includes steps for identifying test compounds that bind to a phage-displayed SH2 domain of interest. This involves incubating the immobilized reference ligand with the SH2 domain in the presence and absence of the test compound, followed by detecting the binding using qPCR amplification. The patent application specifies that the SH2 domain can be a human SH2 domain and that the test compound can bind to specific peptide sequences within the compound or the reference ligand. Additionally, the method allows for testing multiple test compounds simultaneously and at different concentrations, providing a comprehensive screening approach for identifying compounds that interact with the SH2 domain of interest.
To know more about GlobalData’s detailed insights on Eurofins Scientific, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
